STUB1 and early-onset autosomal dominant Alzheimer disease: Although CHIP may not ultimately be a suitable therapeutic approach for PD, it is still a valid approach for other protein-misfolding diseases such as Alzheimer's disease and Huntington's disease and was previously shown to degrade protein aggregates implicated in both diseases [12], [17], [18].